Perspective Therapeutics, Inc. (CATX)
NYSEAMERICAN: CATX · Real-Time Price · USD
2.930
-0.010 (-0.34%)
At close: Jun 16, 2026, 4:00 PM EDT
2.924
-0.006 (-0.20%)
After-hours: Jun 16, 2026, 8:00 PM EDT
Perspective Therapeutics Revenue
Perspective Therapeutics had revenue of $76.00K in the quarter ending March 31, 2026, a decrease of -77.78%. This brings the company's revenue in the last twelve months to $618.00K, down -57.99% year-over-year. In the year 2025, Perspective Therapeutics had annual revenue of $884.00K, down -39.20%.
Revenue (ttm)
$618.00K
Revenue Growth
-57.99%
P/S Ratio
540.70
Revenue / Employee
$3,723
Employees
166
Market Cap
334.16M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 884.00K | -570.00K | -39.20% |
| Dec 31, 2024 | 1.45M | 20.00K | 1.39% |
| Dec 31, 2023 | 1.43M | - | - |
| Dec 31, 2022 | - | - | - |
| Jun 30, 2022 | - | - | - |
| Jun 30, 2021 | 10.05M | 373.00K | 3.85% |
| Jun 30, 2020 | 9.68M | 2.37M | 32.35% |
| Jun 30, 2019 | 7.31M | 1.39M | 23.48% |
| Jun 30, 2018 | 5.92M | 1.16M | 24.41% |
| Jun 30, 2017 | 4.76M | -8.00K | -0.17% |
| Jun 30, 2016 | 4.77M | 163.00K | 3.54% |
| Jun 30, 2015 | 4.61M | 386.84K | 9.17% |
| Jun 30, 2014 | 4.22M | -306.07K | -6.76% |
| Jun 30, 2013 | 4.53M | -545.86K | -10.76% |
| Jun 30, 2012 | 5.07M | -167.88K | -3.20% |
| Jun 30, 2011 | 5.24M | -47.11K | -0.89% |
| Jun 30, 2010 | 5.29M | -131.74K | -2.43% |
| Jun 30, 2009 | 5.42M | -1.74M | -24.32% |
| Jun 30, 2008 | 7.16M | 1.42M | 24.76% |
| Jun 30, 2007 | 5.74M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Orthofix Medical | 825.37M |
| Viemed Healthcare | 286.57M |
| Pacific Biosciences of California | 160.03M |
| Delcath Systems | 90.44M |
| Standard BioTools | 86.26M |
| Electromed | 71.75M |
| 908 Devices | 57.80M |
| Senseonics Holdings | 40.71M |
CATX News
- 13 days ago - Perspective announces first patient dosed with (212Pb)VMT-alpha-NET - TheFly
- 13 days ago - Perspective Therapeutics Expands Therapeutic Focus Areas; First Patient Dosed with [212Pb]VMT-α-NET in the Meningioma Cohort of a Phase 1/2a Study - GlobeNewsWire
- 26 days ago - Perspective Therapeutics to Present Data from All Clinical Programs at the 2026 ASCO Annual Meeting, including Findings from [212Pb]VMT01 in Melanoma - GlobeNewsWire
- 4 weeks ago - Perspective Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026 - Transcripts
- 4 weeks ago - Perspective Therapeutics doses first patients in two Phase 1/2a studies - TheFly
- 4 weeks ago - Perspective Therapeutics Announces First Patients Dosed in New Cohorts of Two Ongoing Phase 1/2a Studies - GlobeNewsWire
- 4 weeks ago - Perspective Therapeutics Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts
- 5 weeks ago - Perspective Therapeutics price target lowered to $6 from $7 at BofA - TheFly